Mixed-phenotype acute leukemia

The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs

Retrieved on: 
Tuesday, December 5, 2023
Multiple myeloma, Bone marrow, Research, TAP, Beat, Food, Mixed-phenotype acute leukemia, Toxicity, ASH, Leukemia, Clinical trial, Leukemia & Lymphoma Society, Patient, Pedal, Troland Research Awards, FDA, Chronic lymphocytic leukemia, Prognosis, Pancreatic serous cystadenoma, RYE, Diagnosis, Survival, AML, Network, Society, Quality of life, Haematopoietic system, Lymphoma, LLS, Pharmaceutical industry, Nursing, Access

RYE BROOK, N.Y., Dec. 5, 2023 /PRNewswire/ -- At the 65th Annual American Society of Hematology (ASH) Annual Meeting (December 9-12 in San Diego), The Leukemia & Lymphoma Society (LLS) will present new research findings, and proudly support more than 200 LLS-funded researchers, as well as 15 current and former LLS Therapy Acceleration Program® (TAP) partners, who will share their study results.

Key Points: 
  • The next big advances are in the works," said Lee Greenberger, Ph.D., LLS Chief Scientific Officer.
  • LLS funding has helped advance more than 70% of blood cancer treatment options approved by the U.S. Food and Drug Administration in the last six years.
  • LLS research selected for presentation at ASH includes:
    New data from two master clinical trials convened and led by LLS: the Pediatric Acute Leukemia Master Clinical Trial ( PedAL ) and the Beat AML® Master Clinical Trial .
  • The Beat AML Master Clinical Trial, the first collaborative precision medicine clinical trial in blood cancer, uses advanced technology to provide genomic analysis to match patients to precision treatment within seven days.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

Retrieved on: 
Tuesday, September 26, 2023
Abstract, Graft-versus-host disease, KOL, University of Chicago, Society, University, ASH, SITC, SNO, Immunotherapy, Pakistan Society of Neuro-Oncology, Transplant, Development, Mixed-phenotype acute leukemia, Johns Hopkins School of Medicine, Leukemia, Webcast, Society for Immunotherapy of Cancer, Conference, Pharmaceutical industry

ET and will be accessible both virtually and in-person in New York, NY.

Key Points: 
  • ET and will be accessible both virtually and in-person in New York, NY.
  • The webcast will also be available under the “Events and Presentations” section of the Company’s website at https://investors.in8bio.com .
  • The event will offer the opportunity to gain Key Opinion Leader (KOL) insights into IN8bio’s clinical and scientific programs along with upcoming catalysts.
  • Following the live event, an archived replay of the webcast will be made available on our website.

The Leukemia & Lymphoma Society Welcomes Five Members to Board of Directors

Retrieved on: 
Monday, July 3, 2023
Carbon, Lymphoma, WCM, University, Moffitt, Gene, Dan, RYE, Pediatrics, Neoplasm, OpenText, Hodgkin lymphoma, Center for Cell and Gene Therapy, Bone marrow, Quality of life, Baylor University, National Cancer Institute, Medicine, Research, Houston Methodist Hospital, LLS, Accounting, Barrenechea, Wood, Mixed-phenotype acute leukemia, Doctor of Science, Ball, Texas Children's Hospital, Patient, Heel, Cell, Weill Cornell Medicine, Biology, Baylor College of Medicine, Hospital, Multiple myeloma, H. Lee Moffitt Cancer Center & Research Institute, FDA, 21st Critics' Choice Awards, Leukemia, III, Pharmacology, Management, Dentistry, Koppers

RYE BROOK, N.Y., July 3, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023:  Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.

Key Points: 
  • RYE BROOK, N.Y., July 3, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023: Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.
  • In his role, and with the dedication and commitment of LLS's Board of Directors, Dr. Kolb is leading the $500 million organization in its mission to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life for blood cancer patients and their families.
  • Leroy M. Ball: Leroy M. Ball is president and chief executive officer of Koppers and serves on the company's Board of Directors.
  • Mark J. Barrenechea: Mark J. Barrenechea joined OpenText as president and chief executive officer in January 2012 and serves as a member of the Board of Directors.

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Sunday, June 11, 2023
Postcholecystectomy syndrome, Menin, Continuity, Venetoclax, Crystal structure, Cancer, Mutation, Massachusetts General Hospital, Kura, MEN1, Acute myeloid leukemia, Congress, Mixed-phenotype acute leukemia, AML, Dor, Patient, KURA, EHA, IDH, FLT3, SCT, CRi, Hospital, Poster, Safety, Disease, Pharmaceutical industry

The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.

Key Points: 
  • The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.
  • Notably, 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib.
  • Two patients underwent a stem cell transplant (SCT) and remain in remission as of the data cutoff, including one on post-SCT ziftomenib maintenance therapy.
  • “The clinical data presented today continue to demonstrate the ability of ziftomenib to drive durable responses as a monotherapy in heavily pretreated patients with NPM1-mutant AML.

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, March 28, 2023
CLL, PDAC, KRAS, Maintenance, Insulin, Food, CRC, Diabetes, Chronic lymphocytic leukemia, Investment, Menin, Multiple myeloma, NPM1, Type 2 diabetes, Mutation, Cancer, G&A, Liraglutide, Lung cancer, B-cell lymphoma, Mixed-phenotype acute leukemia, Investigational New Drug, MLL, Patient, DSM-IV codes, Colorectal cancer, Administration, MM, FLT3, Research and development, R, Research, Phase, FDA, IND, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, DLBCL, NSCLC, Osteopathic medicine in Canada, Glycated hemoglobin

“During 2022 we transformed Biomea from a preclinical company to a fully integrated clinical-stage company, pursuing ten indications, with two distinct molecules in three different trials.

Key Points: 
  • “During 2022 we transformed Biomea from a preclinical company to a fully integrated clinical-stage company, pursuing ten indications, with two distinct molecules in three different trials.
  • I am incredibly proud of our team’s performance and dedication, which has enabled our rapid clinical progress,” said Thomas Butler, CEO and Chairman of Biomea.
  • None of the currently approved therapies for diabetes are effectively addressing the loss and function of beta cells.
  • G&A expenses were $20.9 million for the year ended December 31, 2022, compared to $13.7 million for the same period in 2021.

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Mixed-phenotype acute leukemia, Neoplasm, Incidence, Security (finance), KURA, DNMT3A, Acute leukemia, ASH, FLT3, AML, QT interval, Toxicity, Research, Food, FDA, Safety, Cancer, Bone marrow, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRD, Duke Cancer Institute, IDH, Society, FTI, Therapy, Breakthrough therapy, CRH, KMT2D, News, HRAS, Venetoclax, Element, Disease, Patient, DS, NPM1, CT, Prognosis, Optimus, CR, Survival, Orphan, IND, HNSCC, Risk, Postcholecystectomy syndrome, Pharmaceutical industry, KMT2A

SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML).

Key Points: 
  • These data are being featured during an oral session today at the American Society of Hematology (ASH) Annual Meeting.
  • The patient entered the trial having progressed through seven prior lines of therapy and remains on ziftomenib after two years.
  • ET today, December 10, 2022, following the oral presentation of updated data from the KOMET-001 clinical trial at the ASH Annual Meeting in New Orleans.
  • Ziftomenib, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged AML.

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
MLL, Fast Track, KMT2A, Menin, Webcast, Food, Phenotype, Breakthrough therapy, Orphan, Patient, CR, OS, ALL, FDA, Mixed-phenotype acute leukemia, DOR, Acute lymphoblastic leukemia, CYP3A4, Acute leukemia, COVID-19, AML, Growth, Safety, Risk, Acute myeloid leukemia, Pharmacokinetics, NPM1, Mutation, Pharmaceutical industry

WALTHAM, Mass., Dec. 10, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented updated positive data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A rearranged (KMT2r) relapsed/refractory (R/R) acute myeloid or acute lymphoid leukemias (ALL or AML). Revumenib is the Company's highly selective, oral menin inhibitor. The data were featured during two oral sessions today at the 64th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • Revumenib is currently being evaluated in several clinical trials, including the Company's pivotal AUGMENT-101 Phase 1/2 open-label clinical trial for the treatment of relapsed/refractory (R/R) acute leukemias.
  • Revumenib was also granted Breakthrough Therapy Designation by the FDA for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement.
  • AUGMENT-101 is a Phase 1/2 open-label trial designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of orally administered revumenib.
  • Patients will be enrolled across each of the following trial populations: patients with NPM1 mutant AML, patients with KMT2Ar (MLLr) AML, and patients with KMT2Ar (MLLr) ALL.

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

Retrieved on: 
Thursday, October 6, 2022
LinkedIn, Memorial Sloan Kettering Cancer Center, U.S. Securities and Exchange Commission, Immunology, Doctor of Philosophy, Albert Einstein College of Medicine, Risk, Columbia, Compound, Brain, Johnson & Johnson, Patient, Drug development, Research, Twitter, Graft-versus-host disease, Program, Security (finance), Multimedia, Internal medicine, Nasdaq, Senior, Cancer, D, HER2, Private Securities Litigation Reform Act, Oncology, ALK, Company, NSCLC, Mixed-phenotype acute leukemia, Industry, Board, Breast cancer, Faculty, Chemistry, CNS, NewYork-Presbyterian Hospital, Melanoma, Board of directors, COVID-19, Pharmaceutical industry, Microbiology

CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announcedthe appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announcedthe appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors.
  • Dr. Meyers has established a legacy of industry leadership spanning early-phase development to late-stage life cycle management for both liquid and solid tumors.
  • Prior to this, he served on the faculty at Memorial Sloan Kettering Cancer Center, specializing in clinical immunology and melanoma.
  • We routinely post information that may be important to investors on our website at www.nuvalent.com .Follow us on Twitter ( @nuvalent ) and LinkedIn .

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

Retrieved on: 
Friday, August 26, 2022
MEIS1, IC50, CEO, Safety, Pharmacokinetics, Securities Act of 1933, Research, Gene, DLBCL, Toxicity, Multiple myeloma, Drug Quality and Security Act, TIP, OBD, DLT, U.S. Securities and Exchange Commission, GLOBE, ORR, DEL, Risk, DHL, HOXA9, TTP, Patient, Cardiovascular disease, Menin, Cancer, Protein, AML, Board, Collection, DNA, SEC, Acute leukemia, Securities Exchange Act of 1934, Mixed-phenotype acute leukemia, Progression-free survival, Nasdaq, Diabetes, MLL, PFS, Lists of diseases, Disease, Diffuse large B-cell lymphoma, AL, ECOG, DOR, Annual general meeting, IMS, Growth, B-cell lymphoma, MYC, IND, NRAS, KRAS, THL, Apoptosis, CNS, Vaccine, Pharmaceutical industry, Osteopathic medicine in Canada

We previously reported the ability of BMF-219 to modulate MYC expression and exhibit high potency against Double HIT Lymphoma (DHL) DLBCL (Diffuse Large B Cell Lymphoma) preclinical models.

Key Points: 
  • We previously reported the ability of BMF-219 to modulate MYC expression and exhibit high potency against Double HIT Lymphoma (DHL) DLBCL (Diffuse Large B Cell Lymphoma) preclinical models.
  • Additionally, we provide mechanistic evidence for direct inhibition of menin protein, in cell line models representing MM, DHL and DEL.
  • Collectively, our data demonstrate the novel and robust anti-tumor activity of BMF-219 in HGBCL and MM preclinical models that represent categories of high unmet need.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.